175 related articles for article (PubMed ID: 27904042)
1. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
3. Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Lavolé A; Danel S; Baudrin L; Gounant V; Ruppert AM; Epaud C; Belmont L; Rosencher L; Cadranel J; Milleron B
Bull Cancer; 2012 Apr; 99(4):E43-8. PubMed ID: 22450449
[TBL] [Abstract][Full Text] [Related]
4. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
[TBL] [Abstract][Full Text] [Related]
5. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
6. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
7. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
Mense ES; Smit AAJ; Crul M; Franssen EJF
J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
Lee YG; Lee E; Kim I; Lee KW; Kim TM; Lee SH; Kim DW; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):670-5. PubMed ID: 25672586
[TBL] [Abstract][Full Text] [Related]
9. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Rothschild S; Bucher SE; Bernier J; Aebersold DM; Zouhair A; Ries G; Lombrieser N; Lippuner T; Lütolf UM; Glanzmann C; Ciernik IF
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):126-32. PubMed ID: 20646869
[TBL] [Abstract][Full Text] [Related]
12. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
13. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
14. [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Ogura T; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):89-96. PubMed ID: 9464334
[TBL] [Abstract][Full Text] [Related]
15. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
16. [Utility of the Predictive Score for Cisplatin-Induced Nephrotoxicity in Patients with Chemotherapy for Lung Cancer].
Sakurai T; Takada K; Kojima E; Yamashita Y; Akazawa N; Ito S; Watanabe S
Gan To Kagaku Ryoho; 2019 Dec; 46(12):1849-1853. PubMed ID: 31879402
[TBL] [Abstract][Full Text] [Related]
17. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients.
Lv Y; Ding XS; Li Y; An X; Miao LY
Cancer Biomark; 2016; 16(1):89-97. PubMed ID: 26835709
[TBL] [Abstract][Full Text] [Related]
18. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.
Ikesue H; Watanabe H; Hirano M; Chikamori A; Suetsugu K; Ryokai Y; Egashira N; Yamada T; Ikeda M; Iwama E; Harada T; Takayama K; Nakanishi Y; Masuda S
Biol Pharm Bull; 2015; 38(8):1192-8. PubMed ID: 26235582
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
